| | Business Summary | | Targeted
Genetics
Corp.
develops
gene
therapy
products
and
technologies
for
treating
acquired
and
inherited
diseases.
The
Company
has
two
lead
products
under
development:
tgAAV-cf,
a
treatment
for
cystic
fibrosis;
and
tgDCC-E1A,
a
treatment
for
cancer.
In
addition,
Targeted
Genetics
has
a
promising
pipeline
of
product
candidates
focused
on
hemophilia
A,
arthritis,
cancer,
lysosomal
storage
disease,
cardiovascular
disease
and
AIDS
prophylaxis.
In
addition
to
its
gene
delivery
technologies,
the
Company
has
patents
and
expertise
in
cell
therapy
that
may
prove
to
have
significant
value.
The
Company's
subsidiary,
CellExSys
Inc.,
utilizes
its
cell
therapy
technology
and
expertise
to
isolate
potent,
disease-specific
cytotoxic
T
lymphocytes
from
small
samples
of
patient
blood,
which
can
then
be
expanded
to
large
numbers
for
reinfusion
to
the
patient. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | TGEN
is
a
development
stage
company
engaged
in
the
development
of
gene
and
cell
therapies
for
the
treatment
of
various
genetic
disorders,
cancer
and
infectious
diseases.
For
the
three
months
ended
3/31/01,
revenues
increased
41%
to
$3.8
million.
Net
loss
applicable
to
common
before
acct.
change
totaled
$6.5
million,
up
from
$2.8
million.
Results
reflect
the
initiation
of
a
collaboration
with
Biogen,
Inc.,
offset
by
costs
related
to
the
addition
of
Genovo's
R&D
operations. Recent Earnings Announcement
For
the
3
months
ended
06/30/2001,
revenues
were
4,339;
after
tax
earnings
were
-5,865. (Preliminary; reported in thousands of dollars.) | | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Jeremy Cook, 51
Chairman | -- | H. Parker, 44
Pres,
CEO, Director | $372K | Barrie Carter, Ph.D., 55
Exec.
VP of R&D | 247K | James Johnson, 43
Sr.
VP, Fin. and Admin., CFO, Treasurer and Sec. | 240K | Pervin Anklesaria, Ph.D.
VP,
Research | -- | | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/t/tgen.gif)